<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434561</url>
  </required_header>
  <id_info>
    <org_study_id>2650</org_study_id>
    <secondary_id>4R00HL088021-03</secondary_id>
    <nct_id>NCT03434561</nct_id>
  </id_info>
  <brief_title>Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI</brief_title>
  <official_title>Comparing Different Methods for Collection of Comorbidity Data Per the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comorbidity assessment in the field of HCT might be a burden on the medical team at the
      clinic or the research staff. This research study aims to explore and validate new methods,
      Claims-based and patient questionnaire-based, as alternatives to the standard chart-based
      method in order to facilitate comorbidity coding. The study aims to save time and effort of
      medical personnel and to ensure the inclusion of comorbidity information in all clinical
      trials and outcome research studies in order to improve the accuracy of treatment
      decision-making, patient assignment to appropriate HCT strategy and hence HCT outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown the importance of pre-transplant comorbidities in predicting mortality
      after allogeneic HCT.

      However, comorbidity assessment might be a burden on the medical team at the clinic or the
      research staff. This research study aims to explore and validate new methods as alternatives
      to the standard chart-based method in order to facilitate comorbidity coding. The study aims
      to save time and effort of medical personnel and to ensure the inclusion of comorbidity
      information in all clinical trials and outcome research studies in order to improve the
      accuracy of treatment decision-making, patient assignment to appropriate HCT strategy and
      hence HCT outcomes.

      This study will investigate two parallel approaches aimed at simplifying comorbidity
      assessment and thereby facilitating wide-spread use of the HCT-CI. Patient
      questionnaire-based and Claims-based methods will be tested as possible alternative to the
      Chart-based method. primary outcome is prediction of non-relapse mortality. It is expected
      that once this method of comorbidity coding is validated, it will benefit physicians in
      non-academic institutions and community clinics.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of agreement on HCT-CI scores between 3 measures</measure>
    <time_frame>2 years</time_frame>
    <description>3 measures: the questionnaire-based and the claims-based methods versus the chart-based method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the accuracy of predicting HCT outcomes and resource utilization (e.g., hospitalization) between the three methods of scoring</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">360</enrollment>
  <condition>Hematopoietic Malignancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with hematological malignancies who are being treated with allogeneic
        hematopoietic cell transplantation (HCT) at the Seattle Cancer Care Alliance
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for autologous or allogeneic HCT.

          -  Able to speak and read English.

          -  Willing and able to provide informed consent.

          -  There is no restriction based on diagnosis, intensity of conditioning regimen, type of
             donor graft, degree of HLA-matching, or stem cell source.

          -  Patients &gt;20 years old

          -  Access to a telephone for study-related communications.

        Exclusion Criteria:

          -  HCT candidates who cannot read, write, or speak English.

          -  Patients &lt;20 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Sorror, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Member, Fred Hutch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb R. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004 Aug 15;104(4):961-8. Epub 2004 Apr 27.</citation>
    <PMID>15113759</PMID>
  </reference>
  <reference>
    <citation>Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004 Sep 1;104(5):1550-8. Epub 2004 May 18.</citation>
    <PMID>15150081</PMID>
  </reference>
  <reference>
    <citation>Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008 Aug;67(2):124-32. doi: 10.1016/j.critrevonc.2008.01.013. Epub 2008 Mar 28.</citation>
    <PMID>18375141</PMID>
  </reference>
  <reference>
    <citation>Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6):541-52. Review.</citation>
    <PMID>14657533</PMID>
  </reference>
  <reference>
    <citation>McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010 Apr 10;28(11):1878-87. doi: 10.1200/JCO.2009.25.4821. Epub 2010 Mar 8.</citation>
    <PMID>20212255</PMID>
  </reference>
  <reference>
    <citation>van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005 May;41(7):1051-7.</citation>
    <PMID>15862755</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Di Iorio B, Cillo N, Cirillo M, De Santo NG. Charlson Comorbidity Index is a predictor of outcomes in incident hemodialysis patients and correlates with phase angle and hospitalization. Int J Artif Organs. 2004 Apr;27(4):330-6.</citation>
    <PMID>15163067</PMID>
  </reference>
  <reference>
    <citation>Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke. 2004 Aug;35(8):1941-5. Epub 2004 Jul 1.</citation>
    <PMID>15232123</PMID>
  </reference>
  <reference>
    <citation>Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis. 2003 Jul;42(1):125-32.</citation>
    <PMID>12830464</PMID>
  </reference>
  <reference>
    <citation>Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol. 2004 Feb 18;43(4):576-82.</citation>
    <PMID>14975466</PMID>
  </reference>
  <reference>
    <citation>Lübke T, Mönig SP, Schneider PM, Hölscher AH, Bollschweiler E. [Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer?]. Zentralbl Chir. 2003 Nov;128(11):970-6. German.</citation>
    <PMID>14669119</PMID>
  </reference>
  <reference>
    <citation>Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):357-64.</citation>
    <PMID>12243808</PMID>
  </reference>
  <reference>
    <citation>Sabin SL, Rosenfeld RM, Sundaram K, Har-el G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J. 1999 Aug;78(8):578, 581-4.</citation>
    <PMID>10485151</PMID>
  </reference>
  <reference>
    <citation>Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997 Nov;107(11 Pt 1):1469-75.</citation>
    <PMID>9369392</PMID>
  </reference>
  <reference>
    <citation>Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000 Mar;36(4):453-71. Review.</citation>
    <PMID>10717521</PMID>
  </reference>
  <reference>
    <citation>Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996 Jan;34(1):73-84.</citation>
    <PMID>8551813</PMID>
  </reference>
  <reference>
    <citation>Corser W, Sikorskii A, Olomu A, Stommel M, Proden C, Holmes-Rovner M. &quot;Concordance between comorbidity data from patient self-report interviews and medical record documentation&quot;. BMC Health Serv Res. 2008 Apr 16;8:85. doi: 10.1186/1472-6963-8-85.</citation>
    <PMID>18416841</PMID>
  </reference>
  <reference>
    <citation>Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9. Epub 2005 Jun 30.</citation>
    <PMID>15994282</PMID>
  </reference>
  <reference>
    <citation>Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. doi: 10.1016/j.bbmt.2009.07.004. Epub 2009 Sep 1.</citation>
    <PMID>19896087</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

